Combination chemotherapy of S-1 and taxanes in Korea |
| |
Authors: | Yeul Hong Kim and Hoon-Kyo Kim |
| |
Institution: | (1) Department of Internal Medicine, Korea University, College of Medicine, Seoul, South Korea;(2) Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, 93-6, Ji-dong, Paldal-Gu, Suwon, South Korea; |
| |
Abstract: | Various combination treatments incorporating S-1 are undergoing clinical trials in Korea, especially combinations with taxane,
oxaliplatin, or irinotecan. In a phase I study to estimate the maximum tolerated dose of docetaxel in combination with S-1
administered at a fixed dose of 40 mg/m2 twice daily on days 1–14 of each 3-week cycle in patients with advanced gastric cancer, 60 mg/m2 docetaxel was declared to be the maximum tolerated dose. A phase I/II study of the same schedule of combination chemotherapy
with S-1 plus docetaxel reported doses of S-1/docetaxel of 40/75 mg/m2 as the maximum tolerated dose. In a phase I study of S-1 plus weekly docetaxel, the patients received variable doses of docetaxel
administered intravenously over 1 h on days 1 and 8 and S-1 administered on days 1–14 of each 3-week cycle. The maximum-tolerated
doses of S-1 and docetaxel were determined to be 45 mg/m2 and 35 mg/m2 in this study. A phase I/II study of docetaxel plus S-1 combination chemotherapy from Korea reported a response rate of 43.3%.
Also, a phase II study of paclitaxel plus S-1 as first-line therapy in patients with advanced or relapsed gastric cancer showed
an overall response rate of 49%. The most frequent significant toxicities in combination chemotherapies with taxane plus S-1
were neutropenia and febrile neutropenia. However, nonhematological toxicities were mild to moderate. A taxane plus S-1 combination
regimen could be a new standard regimen for advanced gastric cancer, given its significant activity and favorable toxicity
pattern. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|